Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR - PubMed

Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR

D W Acheson et al. Infect Immun. 1996 Jan.

Abstract

This study addresses a mechanism for inducing systemic immunity to Shiga-like toxins by oral administration of a Shiga-like toxin I B-subunit-expressing Vibrio cholerae vaccine strain [CVD 103-HgR(pDA60)]. Two sets of three rabbits were given either CVD 103-HgR or CVD 103-HgR(pDA60) orally. All rabbits immunized with CVD 103-HgR(pDA60) developed neutralizing serum antibodies to Shiga-like toxin I. None of the controls developed such antibodies.

Similar articles

• A review of the current status of enteric vaccines.

  Levine MM, Noriega F. Levine MM, et al. P N G Med J. 1995 Dec;38(4):325-31. P N G Med J. 1995. PMID: 9522876 Review.

• Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.

  Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, Edelman R, Kaper JB, Cryz SJ, Giannella RA, Schiff G, Levine MM. Tacket CO, et al. Infect Immun. 1999 Dec;67(12):6341-5. doi: 10.1128/IAI.67.12.6341-6345.1999. Infect Immun. 1999. PMID: 10569747 Free PMC article. Clinical Trial.

• Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B.

  Zhu C, Yu J, Yang Z, Davis K, Rios H, Wang B, Glenn G, Boedeker EC. Zhu C, et al. Clin Vaccine Immunol. 2008 Feb;15(2):359-66. doi: 10.1128/CVI.00399-07. Epub 2007 Nov 14. Clin Vaccine Immunol. 2008. PMID: 18003816 Free PMC article.

• Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.

  Kundu J, Mazumder R, Srivastava R, Srivastava BS. Kundu J, et al. FEMS Immunol Med Microbiol. 2009 Jul;56(2):179-84. doi: 10.1111/j.1574-695X.2009.00563.x. Epub 2009 May 5. FEMS Immunol Med Microbiol. 2009. PMID: 19453752

• PaxVax CVD 103-HgR single-dose live oral cholera vaccine.

  Levine MM, Chen WH, Kaper JB, Lock M, Danzig L, Gurwith M. Levine MM, et al. Expert Rev Vaccines. 2017 Mar;16(3):197-213. doi: 10.1080/14760584.2017.1291348. Expert Rev Vaccines. 2017. PMID: 28165831 Review.

Cited by

• Diarrheagenic Escherichia coli.

  Nataro JP, Kaper JB. Nataro JP, et al. Clin Microbiol Rev. 1998 Jan;11(1):142-201. doi: 10.1128/CMR.11.1.142. Clin Microbiol Rev. 1998. PMID: 9457432 Free PMC article. Review.

• In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae.

  Ryan ET, Crean TI, John M, Butterton JR, Clements JD, Calderwood SB. Ryan ET, et al. Infect Immun. 1999 Apr;67(4):1694-701. doi: 10.1128/IAI.67.4.1694-1701.1999. Infect Immun. 1999. PMID: 10085006 Free PMC article.

• Treatment Strategies for Infections With Shiga Toxin-Producing Escherichia coli.

  Mühlen S, Dersch P. Mühlen S, et al. Front Cell Infect Microbiol. 2020 May 6;10:169. doi: 10.3389/fcimb.2020.00169. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32435624 Free PMC article. Review.

• Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections.

  Paton JC, Paton AW. Paton JC, et al. Clin Microbiol Rev. 1998 Jul;11(3):450-79. doi: 10.1128/CMR.11.3.450. Clin Microbiol Rev. 1998. PMID: 9665978 Free PMC article. Review.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information